CORPORATE SYMPOSIA
Thursday, May 4, 2017
Room Gartensaal | |
16:45 - 18:15 | BMS: Rethinking glioblastoma: rational application of immuno-oncology research |
Chair: Michael Weller, Zurich/CH | |
16:45 - 16:55 | Welcome & Introduction |
16:55 - 17:15 | Glioblastoma biology and treatment challenges |
17:15 - 17:40 | Preclinical rationale for I-O-based treatment strategies Michael Lim, Maryland/US |
17:40 - 18:05 | Emerging clinical research for I-O in glioblastoma Wolfgang Wick, Heidelberg/DE |
18:05 - 18:15 | Closing, Q&A Michael Weller, Zurich/CH |
Friday, May 5, 2017
Room Kongresssaal | |
12:30 - 14:00 | Novocure: Gliobastoma Therapy with Tumor-Treating Fields (Optune) |
Chair: Michael Weller, Zurich/CH | |
12:35 - 12:40 | Welcome & Introduction Michael Weller, Zurich/CH Maciej M. Mrugala, Phoenix/US |
12:40 - 12:55 | Biological effects of TTFields in glioblastoma Patrick Roth, Zurich/CH |
12:55 - 13:15 | The EF-14 newly diagnosed GBM study in the context of clinical trials: an overview about the current situation in glioblastoma treatment David Reardon, Boston/US |
13:15 - 13:35 | Optune® in daily clinical practice – chances and challenges European perspective |
13:35 - 13:50 | Outlook: TTFields in other indications Giovanni Luca Cresoli, Bergamo/IT |
13:50 - 14:00 | Q&A / Closing remarks / Take away messages Michael Weller, Zurich/CH |
18:15 - 19:45 | Scientific Symposium sponsored by MSD |
Chair: Michael Weller, Zurich/CH | |
18:15-18:20 | Welcome & Introduction |
18:20-18:40 | Role of MGMT testing: Role in clinical trial design and clinical practice Wolfgang Wick, Heidelberg/DE |
18:40-19:00 | Overview on current immunotherapy efforts in gliomas Michael Weller, Zurich/CH |
19:00-19:20 | How immunotherapy can be best integrated into current standards of care David Reardon, Boston/US |
19:20-19:40 | Q&A Panel Discussion Faculty |
19:40-19:45 | Closing Remarks Michael Weller, Zurich/CH |
Saturday, May 6, 2017
Room Kongresssaal | |
12:15 - 13:15 | MagForce: Focal therapy in glioblastoma - current status, what's new? |
Chair: Michael Weller, Zurich/CH | |
12:15 - 12:30 | Introduction, Current state of the art for glioma treatment Michael Weller, Zurich/CH |
12:30 - 12:45 | Focal Therapy in Gliomas – Latest Update Michael A. Vogelbaum, Cleveland/US |
12:45 - 13:00 | New Aspects of Thermotherapy in Brain Tumors – NanoTherm Therapy Walter Stummer, Münster/DE |
13:00 - 13:15 | Discussion Faculty |
15:15 - 16:15 | Mundipharma: Neoplastic meningitis: a new look at a neglected problem |
Chair: Michael Weller, Zurich/CH | |
15:15 - 15:20 | Welcome & Introduction Michael Weller, Zurich/CH |
15:20 - 15:35 | Evaluating patients outcome – experience of the German registry Agnieszka Korfel, Berlin/DE |
15:35 - 15:50 | Defining the scope of the problem – learnings of the the NeMeRe registry Michael Glantz, Hershey/US |
15:50 - 16:05 | Should intra-cerebrospinal therapy be a part of treatment in leptomeningeal metastasis from solid tumors? Emilie Le Rhun, Lille/FR |
16:05 - 16:15 | Discussion Michael Weller, Zurich/CH |
16:30 - 18:00 | Abbvie: Forging new paths in the treatment of glioblastoma |
Chair: Michael Weller, Zurich/CH | |
16:30 - 16:35 | Introduction Michael Weller, Zurich/CH |
16:35 - 16:55 | Management of glioblastoma: standards of care and future directions Michael Weller, Zurich/CH |
16:55 - 17:15 | Biological significance of EGFR in glioblastoma Ken Adalpe, Toronto/CA |
17:15 - 17:35 | EGFR-targeted therapy of glioblastoma: the next 5 years |
17:35 - 17:55 | Panel discussion and Q&A |
17:15 - 17:35 | Closing comments |